OSTF1

OSTF1 (SH3P2/OSF) is an intracellular SH3-domain-containing adaptor protein that acts as a negative regulator of cell motility and osteoclast differentiation (PMID:21501342, PMID:32916757). It engages the actin-coupled signaling machinery through its SH3 domain, binding c-Src with high affinity and associating with Cbl at a specific polyproline motif, where c-Src and OSTF1 mutually compete for monomeric Cbl; in adherent cells it localizes with filamentous actin at focal contacts in fibroblasts and at the apical podosome rings of osteoclasts (PMID:10092216, PMID:15135048). OSTF1's suppressive activity is gated by ERK-pathway signaling: RSK phosphorylates OSTF1 at Ser202, and this phosphorylation relieves its inhibition of cell motility, whereas the non-phosphorylatable S202A mutant constitutively suppresses tumor cell migration (PMID:21501342). In osteoclasts, RANKL stimulation drives OSTF1 dephosphorylation, increasing its binding to myosin 1E (Myo1E) and preventing Myo1E from reaching the plasma membrane, thereby restraining osteoclast differentiation and cell fusion (PMID:32916757); the motility regulator RP2 counteracts this by recruiting OSTF1 to the membrane and sequestering it from Myo1E, an interaction abolished by a pathogenic RP2 mutation (PMID:29361551). Consistent with this restraining role in bone, Ostf1-knockout mice display altered trabecular bone mass and enhanced osteoclastogenesis (PMID:28936620, PMID:32916757). OSTF1 also modulates IL-1β-induced chondrocyte apoptosis, inflammation, and extracellular matrix degradation through the NF-κB pathway (PMID:38699012).

1. 1998 Medium

   Established OSTF1 as an osteoclast-derived intracellular SH3/ankyrin-repeat protein that influences osteoclast formation and binds c-Src, placing it in Src-mediated signaling.

   Evidence Expression cloning with conditioned-media osteoclast formation and bone resorption assays plus recombinant c-Src binding

   PMID:10092216

   Open questions at the time

   • Stimulatory effect was indirect via conditioned media, not a defined molecular mechanism
   • Direct cellular role of the c-Src interaction not resolved
2. 2004 Medium

   Defined OSTF1's physical partnerships, showing it binds Cbl through a polyproline motif shared with Src and localizes to actin-rich focal contacts and podosome rings.

   Evidence Reciprocal Co-IP, pulldowns, Cbl polyproline mutagenesis, and immunofluorescence in fibroblasts and osteoclasts

   PMID:15135048

   Open questions at the time

   • Functional consequence of the Cbl/Src competition not established
   • Single lab, no structural detail of the interface
3. 2011 High

   Identified OSTF1 as a negative regulator of cell motility and uncovered the regulatory switch: RSK phosphorylation of Ser202 downstream of ERK inactivates its motility-suppressing function.

   Evidence Gain/loss-of-function in HeLa S3 and tumor lines, S202A mutagenesis, RSK/MEK kinase inhibitors, and phosphorylation mapping

   PMID:21501342

   Open questions at the time

   • Downstream effector through which OSTF1 suppresses motility not yet identified
   • Phosphatase reversing Ser202 not defined
4. 2017 High

   Provided in vivo confirmation that OSTF1 regulates bone, with knockout mice showing altered trabecular bone mass and broad vascular/tissue expression.

   Evidence Ostf1 LacZ-knockout mouse with bone phenotyping and X-Gal expression mapping

   PMID:28936620

   Open questions at the time

   • Cellular mechanism linking OSTF1 loss to bone phenotype not dissected here
   • Functional relevance of widespread vascular expression unexplored
5. 2018 High

   Connected OSTF1 to RP2 and Myo1E, showing RP2 recruits OSTF1 to the membrane to sequester it from the motility regulator Myo1E, with a disease-relevant interface.

   Evidence Co-IP, pulldowns, structure-based interface mapping, pathogenic RP2 mutation analysis, and motility assays

   PMID:29361551

   Open questions at the time

   • Physiological consequences of the RP2–OSTF1 axis in retinal tissue not addressed
   • How RP2 binding and Myo1E binding are spatially coordinated unclear
6. 2020 High

   Defined the osteoclast mechanism: RANKL-induced OSTF1 dephosphorylation enhances Myo1E binding, blocking Myo1E membrane localization to suppress osteoclast differentiation.

   Evidence Knockout mice, membrane fractionation, Co-IP, Myo1E knockdown rescue, and M-CSF/RANKL osteoclast differentiation assays

   PMID:32916757

   Open questions at the time

   • Identity of the RANKL-activated phosphatase acting on OSTF1 not established
   • How Myo1E membrane localization promotes osteoclast fusion mechanistically unresolved
7. 2024 Medium

   Extended OSTF1 function to chondrocytes, where its knockdown blunts IL-1β-driven apoptosis, inflammation, and matrix degradation via NF-κB.

   Evidence siRNA knockdown in IL-1β-stimulated chondrocytes, OA rat ACLT model, western blot, and RNA-seq

   PMID:38699012

   Open questions at the time

   • NF-κB pathway placement is partly bioinformatic, lacking direct mechanistic linkage
   • Whether the SH3/Myo1E/Cbl axis operates in chondrocytes is untested

• The phosphatase that dephosphorylates OSTF1 Ser202 downstream of RANKL, and the unifying molecular pathway connecting its motility, osteoclast, and NF-κB roles, remain undefined.
• No identified phosphatase reversing Ser202
• No structural model of OSTF1's SH3 domain bound to its partners
• Mechanistic integration across cell types not established